NCT06384222View on ClinicalTrials.gov

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 9, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
High Risk Prostate CarcinomaProstate Cancer
Interventions
DRUG

Abiraterone acetate

Given orally

DRUG

Prednisone

Given orally

DRUG

Hyperpolarized [1-13C] pyruvate (HP 13C)

Given IV

PROCEDURE

Magnetic Resonance Imaging (MRI)

Imaging procedure

PROCEDURE

Non-investigational radical prostatectomy (RP)

Planned, standard of care surgical procedure occurring outside of this study.

PROCEDURE

Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT)

Imaging procedure

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

Ivan de Kouchkovsky, MD

OTHER